Applications of 5-Aza-2'-Deoxycytidine in Industrial Manufacturing

As a dedicated manufacturer of 5-Aza-2'-Deoxycytidine, we supply this active raw material to global partners engaged in advanced biochemical and pharmaceutical manufacturing. The following sections outline the principal downstream industrial applications, focusing on specialized process integration, compliance frameworks, technical formulation ratios, and actual end-use product categories.

1. Oncology Research and Anticancer Drug Development

Pharmaceutical manufacturers use 5-Aza-2'-Deoxycytidine as a key active pharmaceutical ingredient (API) for cytidine analog-based anticancer therapies, particularly in treatments for hematologic malignancies like myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Integration typically starts at the API synthesis stage, where rigorously monitored impurities and residual solvents determine the compound’s suitability for regulatory submission and commercial-scale active substance manufacture.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice Guidelines for APIs
• United States Pharmacopeia (USP) Monograph for Decitabine
• European Pharmacopoeia (Ph. Eur.) requirements
• FDA 21 CFR Part 210/211 for finished pharmaceuticals

Typical usage ratio

• API to bulk formulation: 1%–5% depending on dosage strength per tablet or injectable unit
• Adjustment based on targeted therapeutic dose and bioavailability studies

Downstream process integration

• API crystallization and purification after synthesis
• Direct blending into tablet compression or lyophilization for injectable vials
• In-line QC and HPLC verification prior to batch release

Final product types

• Oral tablets for MDS and AML therapies
• Injectable lyophilized vials for systemic anticancer use
• Regulated finished drugs for clinical and hospital distribution

2. DNA Methylation Research Tool Production

Biotechnology product manufacturers utilize the compound extensively in the production of demethylating agent kits and molecular biology reagents. These products enable accurate in vitro study of epigenetic modifications, providing research institutions with standardized means to analyze DNA methylation patterns. Manufacturing involves precise control of storage and formulation to avoid degradation and ensure consistency across reagent batches.

Industry compliance standards

• ISO 13485:2016 Medical Devices – Quality Management Systems for research use only (RUO) reagents
• OECD Guidelines for Good Laboratory Practice (GLP)
• Labeling and handling as per GHS (Globally Harmonized System)

Typical usage ratio

• 0.1–10 μM working concentration in buffer systems of research kits
• Bulk formulation at 99.5% purity or higher

Downstream process integration

• Dissolution into buffered aqueous systems during kit assembly
• Filtration and aliquoting for single-use research applications
• Sealing in controlled atmosphere packaging to prevent hydrolysis

Final product types

• DNA methylation inhibition reagent kits
• Cell culture supplement sets for pluripotency studies
• Ready-to-use small molecule screening tools

3. Preclinical Drug Screening and Toxicology Testing

Contract research organizations (CROs) and laboratory service providers incorporate 5-Aza-2'-Deoxycytidine as a reference compound for screening of DNA hypomethylating agent activity and for toxicology profiling in cell line and animal studies. Processing requires tight control on solution stability, pH, and concentration fidelity to provide reliable analytical data and cross-lab comparability for regulatory dossiers.

Industry compliance standards

• OECD Principles of Good Laboratory Practice (GLP)
• U.S. FDA GLP (21 CFR Part 58) and EU Directive 2004/9/EC
• ISO/IEC 17025:2017 for laboratory testing competence

Typical usage ratio

• 1–100 μM assay concentrations in in vitro panels
• Up to 10 mg/kg in preclinical animal dosing (per study protocol)

Downstream process integration

• Preparation into stock solutions immediately prior to cell or animal assay
• Sterile filtration into vials for dosing or microplate addition
• Use in blinded QC and batch stability tracking

Final product types

• Bioanalytical reference standards
• Control solutions for high-throughput screening
• Validated toxicological assay kits

4. Cell Therapy and Regenerative Medicine Manufacturing

Manufacturers of cell and gene therapy products employ 5-Aza-2'-Deoxycytidine to modulate cellular epigenomes during in vitro expansion and differentiation of stem cells or engineered cell populations. Under strict GMP cell therapy guidelines, the material supports chromatin remodeling protocols used to preserve therapeutic functionality and lineage specificity through multiple expansion cycles.

Industry compliance standards

• EU GMP Annex 1 for Advanced Therapy Medicinal Products (ATMPs)
• U.S. FDA 21 CFR 1271 for Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)
• ISO 20399:2022 – Bioprocessing and cell therapy logistics

Typical usage ratio

• 0.5–5 μM during in vitro expansion phase of cell processing
• Specific dosing protocols based on target cell types and intended differentiation outcome

Downstream process integration

• Addition to stem cell expansion media under controlled culture conditions
• In-process cell quality testing for epigenetic marker expression
• Removal or dilution before harvest and formulation for patient administration

Final product types

• Engineered hematopoietic stem cell grafts for clinical use
• Mesenchymal stem cell-based regenerative implant materials
• Personalized cellular therapeutics for oncology and tissue repair